has joined the slew of companies developing antibody-drug conjugates (ADC) with the announcement of a new global licensing agreement with for the development of the latter鈥檚 STRO-003.
Ipsen declared that the deal would give it exclusive worldwide rights to develop and commercialise the ROR1-targeting ADC STRO-003. Ipsen is accountable for Phase I preparations, including investigational new drug application (IND) submissions. The Paris, France-headquartered company will also be responsible for the later clinical development and global commercialisation of STRO-003.
Under the partnership, Sutro Biopharma could receive up to $900m in prospective upfront, development, and commercial milestone-based payments. This is inclusive of $90m in near-term payments in the form of tiered royalties on global sales, and an equity investment, dependent on Ipsen鈥檚 successful development and commercialisation strategy.
STRO-003 is one of three named ADCs being developed in Sutro鈥檚 clinical pipeline. In June 2023, to submit INDs for STRO-003 in 2024 and another ADC, STRO-004, in 2025.
In a 1 April company press release, Mary Jane Hinrichs, Ipsen鈥檚 head of early development said, 鈥淭he potential for ADCs in oncology is well-documented and we are excited by the addition of STRO-003, Ipsen鈥檚 first ADC candidate with best-in-class potential.鈥�
ADC development has risen in the pharmaceutical industry in recent years with major companies signing high-value deals to gain assets in the modality. In December 2023, Johnson and Johnson signed a $1.7bn licensing deal to acquire an ADC from the South Korean biotech LegoChem. Similarly, spent an exorbitant $8.4bn on an ADC deal with SystImmune in the same month.
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Thank you!
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form
By GlobalData
